Pipeline
Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancers.
Ratio’s pipeline of therapeutic and diagnostic radiopharmaceuticals targets a variety of cancer indications. Ratio is proud to be partnered with pharmaceutical companies Novartis, Lantheus and Merck.
Learn more about our Platforms and Technology